Patent extension policy for paediatric indications
Richard Nelson (),
Diana Brixner and
Applied Health Economics and Health Policy, 2011, vol. 9, issue 3, pages 171-181
Makers of the branded drugs evaluated were given market exclusivity extensions for conducting studies of their medications in children. The costs found in this study are just a small portion of the total paid, which include those born by other payers. Whether the benefits of this policy outweigh these costs is an open question, but these results suggest that the costs to Medicaid and thus taxpayers are substantial. Copyright Adis Data Information BV 2011
References: View references in EconPapers View complete reference list from CitEc
Citations Track citations by RSS feed
Downloads: (external link)
Access to full text is restricted to subscribers.
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: http://EconPapers.repec.org/RePEc:spr:aphecp:v:9:y:2011:i:3:p:171-181
Ordering information: This journal article can be ordered from
Access Statistics for this article
Applied Health Economics and Health Policy is currently edited by Timothy Wrightson
More articles in Applied Health Economics and Health Policy from Springer
Series data maintained by Sonal Shukla ().